Sequencing efforts led to the identification of somatic mutations that could affect the self-renewal and differentiation of cancer-initiating cells. One such recurrent mutation targets the binding pocket of the ubiquitin ligase Fbxw7. Missense FBXW7 mutations are prevalent in various tumors, including T cell acute lymphoblastic leukemia (T-ALL). To study the effects of such lesions, we generated animals carrying regulatable Fbxw7 mutant alleles. Here, we show that these mutations specifically bolster cancer-initiating cell activity in collaboration with Notch1 oncogenes but spare normal hematopoietic stem cell function. We were also able to show that FBXW7 mutations specifically affect the ubiquitylation and half-life of c-Myc protein, a key T-ALL oncogene. Using animals carrying c-Myc fusion alleles, we connected Fbxw7 function to c-Myc abundance and correlated c-Myc expression to leukemia-initiating activity. Finally, we demonstrated that small-molecule-mediated suppression of MYC activity leads to T-ALL remission, suggesting an effective therapeutic strategy.
INTRODUCTION
As next-generation sequencing studies identify novel genetic lesions in cancer, it becomes evident that mutations affecting key regulators of diverse cellular processes ranging from metabolism to protein stability are somatically selected in cancer cells (Downing et al., 2012; Hodis et al., 2012; Zhang et al., 2012) . Presumably, these mutations are selected for because they bestow cells with tumorigenic properties while sparing their essential functions. Heterozygosity of such mutations further complicates their study, given that it suggests that either small protein expression differences can have profound outcomes or missense mutants might have neomorphic and/or dominantnegative functions. Moreover, mutations rarely act in isolation but, instead, act in a synergistic manner with additional oncogenic lesions. Thus, it is vital to study the impact of somatic missense mutations with genetic models closely mimicking the corresponding human cancer genotypes and to consider the in vivo effects of mutational cooperation.
FBXW7 is mutated in a significant portion of human tumors, including approximately 20% of patients with T cell acute lymphoblastic leukemia (T-ALL) (Akhoondi et al., 2007; O'Neil et al., 2007; Thompson et al., 2007) . Fbxw7 is a constituent of the SCF (Skp1-Cul1-F box) ubiquitin ligase complex that controls the degradation and half-life of key cellular regulators, including Cyclin E, Notch1, c-Myc, and Mcl1 Wang et al., 2012) . Mutations in FBXW7 are predominantly heterozygous and cluster within the WD40 substrate-binding domain, specifically affecting three highly conserved arginine residues (Nash et al., 2001) . Although the outcome of expressing these particular mutations in somatic tissues remains unknown, monoallelic deletion of Fbxw7 in the hematopoietic system fails to induce leukemia. Although complete deletion can lead to T-ALL establishment, albeit with low penetrance (Matsuoka et al., 2008) , the prevailing phenotype of Fbxw7 loss is a progressive bone marrow (BM) failure that eventually leads to fatal anemia. These findings imply that FBXW7 missense mutants are not simply ''dead'' alleles and could behave differently in normal and malignant cells. Accordingly, nonsense FBXW7 mutations are relatively rare in T-ALL (O'Neil et al., 2007; Thompson et al., 2007) . Although the biochemical mechanism behind FBXW7 mutations in T-ALL remains unclear, our group and others have found that these lesions affect the stability of Notch1, the main T-ALL oncogene, which is mutated in approximately half of T cell leukemia patients (Weng et al., 2004) . In agreement with this notion, approximately 25% of NOTCH1 mutations in T-ALL truncate the protein deleting the conserved degron sequence recognized by Fbxw7. Similar mutations in either NOTCH1 or FBXW7 genes are also found in a larger number of additional cancer types, including marginal B cell lymphoma and melanoma (Hodis et al., 2012; Rossi et al., 2012) , making the thorough understanding of their function critical for future therapies.
To study the transforming effects of such missense mutations in vivo, we have generated mice that carry Cre-inducible Fbxw7 heterozygous mutants, mimicking the most common substitution found in human T-ALL (R465C). Interestingly, in contrast to previous knockout models, these mutations did not compromise normal hematopoietic stem cell (HSC) function but lead to a marked increase in the proportion of leukemia-initiating cells (LICs) due to the stabilization of the Fbxw7 substrate c-Myc. Using animals expressing fluorescent c-Myc fusion proteins (Myc GFP ), we were able to show a perfect correlation between c-Myc stabilization and leukemia-initiating activity. Moreover, we were able to demonstrate that c-Myc deletion in established T-ALL specifically ablates LICs and that the inhibition of c-Myc induction with small-molecule BET inhibitors targeting Brd4 (Filippakopoulos et al., 2010; Zuber et al., 2011) can suppress the growth of mouse and human T-ALL cells. Finally, direct c-Myc and Brd4 gene targets in T-ALL were identified genome wide and suggested an intriguing transcriptional cooperation between these factors and Notch1. Altogether, these studies identify FBXW7 R465C as a unique type of somatic mutation, given that it has the ability to specifically alter cancer-initiating cell activity without consequence to normal stem cell differentiation.
RESULTS

Generation of Inducible Knockin Models of FBXW7 Missense Mutations
To test the function of FBXW7 mutations in vivo, we targeted the most common recurrent mutation, an arginine-to-cysteine change at position 465 (468 in the mouse) . Given that mice that harbor a similar germline mutation in Fbxw7 die perinatally because of defects in lung development (Davis et al., 2011) , we generated mutant alleles that could be conditionally activated with the Cre-lox system. Using homologous recombination, we generated an R468C mutation in the endogenous Fbxw7 gene and inserted a lox-STOP-lox cassette in the upstream intron, thereby functioning as a null allele prior to recombination and as a mutant in all lineages where Cre is activated (Figure S1A available online). Fbxw7
R468Neo/+ pups were born and developed normally, yet Fbxw7
R468Neo/R468Neo mice were never represented, which was consistent with reports that Fbxw7-null mice die in utero (Tsunematsu et al., 2004) . Mice were crossed to the pI:pC-inducible Mx1-Cre allele (Kü hn et al., 1995) . Recombination was observed in the genomic DNA of BM cells, and the mutation could be detected in messenger RNA (mRNA) (Figures S1B-S1C) after pI:pC treatment. Alternatively, to study the effect of the exact human R465C mutation, we introduced an exogenous human FBXW7 R465C complementary DNA (cDNA) (with an N-terminal FLAG tag) in the ubiquitously expressed elongation factor 1 alpha (Eef1a1) locus . As with the endogenous mouse Fbxw7 mutant, this targeting positioned a lox-STOP-lox cassette upstream of the mutant cDNA for conditional activation (Figure S1D) . Upon Cre induction, we could detect robust expression of a 110 kDa protein by FLAG immunoblot in lysates from primary tissues ( Figure S1E ). Furthermore, the mutant human Fbxw7 was functional and incorporated into the SCF complex, whereas other components (Skp1 and Cul1) could be coimmunoprecipitated (data not shown). As will become evident from the following studies, both alleles (Fbxw7 R468 and Eef1a1
mutW7
) yield similar phenotypes. Most of the presented studies will focus on the Fbxw7 R468 endogenous allele (referred as Fbxw7 mut ).
FBXW7 Mutations Do Not Affect Normal HSC and Progenitor Differentiation
Previous studies have shown that conditional deletion of Fbxw7 in the adult hematopoietic system leads to a rapid depletion of HSCs and T cell progenitors (Matsuoka et al., 2008; Thompson et al., 2008) . Given that HSCs provide a long-lived reservoir of cells with an inherent capacity for self-renewal, it has been hypothesized that many of the oncogenic lesions found in hematopoietic malignancies might arise in HSCs or multipotent progenitors (Francis and Richardson, 2007; Mohrin et al., 2010) . However, this presents a paradox for FBXW7 mutations in particular, given that these mutations could be deleterious for normal hematopoiesis and selected against prior to transformation. To test the possibility that heterozygous Fbxw7 mutations might be tolerated differently than deletion of one or both alleles, we assessed HSC function in Fbxw7 , given that they generated a greater number of colonies in colony-forming assays ( Figure 1C ) and reconstituted recipient mice to the same extent as Fbxw7 D/+ donors upon competitive BM transplantation ( Figure 1D) . Moreover, the depletion of early T cell progenitors typically seen in Fbxw7 D/D thymii was also absent in Fbxw7 mut/+ mice (Figure 1E) , demonstrating that the mutant progenitors could colonize the Fbxw7-deficient thymus and differentiate normally.
Fbxw7-deficient HSCs fail to self-renew primarily because of an aberrant accumulation of c-Myc protein . To test whether differential c-Myc abundance could account for the inability of the mutant allele to affect hematopoiesis, we determined the level of c-Myc protein in HSC of each genotype by crossing the Fbxw7 mut and Fbxw7 F/F Mx1-Cre strains to a mouse expressing a c-Myc:GFP fusion from the endogenous Myc locus (Myc GFP ) (Huang et al., 2008) . Intriguingly, the level of c-Myc stabilization in mutant HSCs was significantly greater than that ofFbxw7 D/+ but still lower than that observed in Fbxw7-deficient HSCs ( Figures 1F-1G ). Altogether, these data imply that the intermediate levels of c-Myc stabilization resulting from a heterozygous Fbxw7 mutation are tolerated in HSCs, whereas the level of c-Myc in Fbxw7-deficient HSCs surpasses a threshold that is incompatible selfrenewal. Figures 2B and 2C ). In addition, a greater proportion of these blasts were actively cycling, as exhibited by more prominent Ki67 staining (Figures 2D and 2E) . Because the extent of maturation of T-ALL often correlates with a poorer prognosis (Ferrando and Look, 2003; Zhang et al., 2012) , the expression of surface markers corresponding to different stages of physiological T cell development was compared between genotypes. A noticeable trend in decreased CD4 and, to a lesser extent, CD8 surface expression was observed in the Fbxw7 mutant leukemias (Figure 2F) , suggesting a more immature (and potentially aggressive) phenotype. Given that Notch1 is an Fbxw7 substrate, we repeated the presented leukemia-induction experiments using human Notch1-DPEST mutants (Chiang et al., 2008) , which are lacking the C-terminal region bound by Fbxw7. As seen in Figure 2G , Fbxw7 mut/+ Notch1 DPEST tumors also developed with significantly shorter latency, suggesting that additional Notch stabilization alone could not explain the aggressiveness of the disease. Initial attempts to serially transplant the disease revealed that the Fbxw7 mut leukemias were more efficient in generating secondary tumors ( Figure 2H ). Thus, we hypothesized that the frequency of LICs might be higher within the Fbxw7 mut leukemia.
To quantify the LIC frequencies in Fbxw7 mutant or WT T-ALL, we transplanted equivalent numbers of GFP + cells sorted from leukemias arising from either genotype into secondary recipients at a range of doses from 10 4 -10 6 cells per recipient. All of the mice transplanted with 10 6 cells, regardless of Fbxw7 status, eventually developed leukemia. However, the frequency of leukemia in mice that received 2 3 10 5 or 5 3 10 4 cells was significantly higher in the Fbxw7 mutant cohorts (100% versus 11% and 75% versus 0%, respectively) ( Figure 2H ). Using limiting dilution analysis (Buchstaller et al., 2012) , we calculated that the LIC frequency within the Fbxw7 mutant T-ALL was more than 10-fold higher than in Fbxw7 WT T-ALL ( Figure 2I ).
FBXW7 Mutations Do Not Lead to Genomic Instability or Cooperate with p53 Loss
Previous studies observed genomic instability in human cancer cells when FBXW7 was deleted (Grim et al., 2012; Rajagopalan et al., 2004) . To test whether chromosomal abnormalities were contributing to leukemia development in vivo, we utilized metaphase fluorescent in situ hybridization (mFISH) to karyotype Fbxw7 mutant leukemias. However, the vast majority of tumor cells had a normal karyotype ( Figure S2A ). To test for smaller genomic events, we analyzed DNA from leukemic cells by array-comparative genomic hybridization (array CGH). Several Fbxw7 mutant or WT leukemias were analyzed, and normal tissue from donor mice was used as a reference. Between both groups of samples, the only significant DNA gain or loss consistently found was within the Tcra locus ( Figure S2B ), which was in agreement with the identity and developmental stage of the leukemia. Although neither of these results rule out the possibility of collaborating point mutations, genetic instability is unlikely to be responsible for the more aggressive nature of Fbxw7 mutant leukemias. In addition to activating mutations in Notch1, Fbxw7 has been genetically associated with the inactivation of p53 in a number of tumor models (Grim et al., 2012; Onoyama et al., 2007) . To determine whether loss of p53 could collaborate with our Fbxw7 mutant allele, we transduced Fbxw7
BM with a retroviral small hairpin RNA (shRNA) targeting Trp53. The WT or Fbxw7 D/D donors generated tumors in recipient animals with a time of onset and disease phenotype that coincided with the previous genetic models ( Figure S2C ). However, the latency of leukemia development was not decreased by the mutation of Fbxw7, despite the efficient silencing of Trp53 (Figure S2D) . Therefore, there is a clear disparity between Fbxw7-null and Fbxw7 R465C mutants in the requirement for p53 inactivation. Moreover, unlike NOTCH1, TP53 mutations are not enriched in FBXW7 mutant human T-ALL , thus supporting our findings with the Fbxw7 mut animal models.
FBXW7 Mutations Affect c-Myc Protein Half-Life and Ubiquitylation
Having ruled out genomic instability, we sought to determine the mechanism by which Fbxw7 mutations confer a greater leukemia initiating capacity to cells uniformly expressing a Notch1 Figure S3A ). Of the substrates tested, we noted moderate stabilization of Notch1 and Srebp1 and a very consistent and significant stabilization of c-Myc ( Figure S3A ). Myc has an essential role in cell growth and self-renewal (Eilers and Eisenman, 2008; Murphy et al., 2005) and has previously been implicated in the pathogenesis of T-ALL as a transcriptional target of Notch1 (Palomero et al., 2006; Sharma et al., 2006) . Thus, we focused on the putative mechanisms of c-Myc stabilization by the mutant Fbxw7 allele. In an in vitro ubiquitylation assay, the R465C mutation renders Fbxw7 incapable of ubiquitylating c-Myc (Figure S3B ). Given that SCF-Fbxw7 complexes have been shown to dimerize in certain conditions (Welcker and Clurman, 2007) Figure S4A ) and rare in the spleen ( Figure 3A) . Strikingly, this population was typically 10-fold larger in the Fbxw7 mutant leukemia ( Figure 3A) . Figure S4B ). As the leukemia progressed, the Myc GFP+ population became more abundant, but it never achieved a majority ( Figure S4C ). Interestingly, between hematopoietic and lymphoid organs, the highest frequency of Myc GFP+ cells was consistently observed in the spleen ( Figure S4D Figure 3B ). More importantly, the cohort transplanted with Myc GFPÀ cells exhibited 100% leukemia-free survival, whereas the Myc GFP+ cohort all succumbed to T-ALL by 6 weeks after transplant ( Figure 3C ). Importantly, secondary leukemias arising from the Myc GFP+ cohort re-established the heterogeneity of the primary tumor, including both Myc GFP+ and Myc GFPÀ cells ( Figure S4G ), demonstrating that Myc GFP+ cells can self-renew and differentiate-the defining properties of a cancer stem cell. Altogether, these data define c-Myc protein abundance a bona fide LIC marker in a T-ALL mouse model and suggest that this population is heavily dependent on Fbxw7 activity. To test whether this observation translates to human T-ALL, CD34 + populations enriched for T-ALL LICs (Armstrong et al., 2009) were purified from human patient samples that carry NOTCH1 and FBXW7 mutations. In agreement with the mouse data, non-LIC subsets expressed significantly lower levels of c-Myc protein in comparison to the CD34 + fraction ( Figure 3D ) despite no increase in MYC mRNA ( Figure 3E ) or cleaved Notch1. c-Myc levels were higher in samples carrying FBXW7 mutations, further supporting the notion that missense FBXW7 mutations augment c-Myc protein stability in T-ALL.
T-ALL LICs Are Defined by a Myc Gene Expression Signature To study this subpopulation enriched in T-ALL LIC activity further, we sought to determine its underlying molecular signature using gene expression analysis. Total RNA was isolated from either Myc GFP+ or Myc GFPÀ leukemic cells, and gene expression was determined by microarray analysis ( Figure 3F ). The most represented group among the top upregulated genes included those involved in the mitotic phase of the cell cycle (Cdc6, Ccnb1, Chek1, Aurkb, and Brca1) and, as expected, transcriptional targets of c-Myc (Cad, Suv39h2, Bcat1, and Pa2g4) (Kim et al., 2008; Margolin et al., 2009) . Also, many genes encoding cell-surface markers (Fas, Slamf1, Il7r, and Cd4), which may be helpful for further thorough dissection of the LIC population, differed significantly at the mRNA level between the two populations. Gene set enrichment analysis (GSEA) was performed in order to identify gene modules that are enriched within the Myc GFP+ population ( Figure 3G ). Gene sets pertaining to stem cell identity, including common genes upregulated in adult and embryonic stem cell (ESC) populations, as well as a set of c-Myc-regulated genes in both ESCs and human cancers (Kim et al., 2008) , were highly enriched ( Figure 3F ). Gene sets associated with early T cell progenitors , and undifferentiated tumors (Rhodes et al., 2004) were also enriched. Fbxw7, on the other hand, was significantly downregulated in the Myc GFP+ population ( Figure 3F ), suggesting that, in the absence of mutations, there is a need to transcriptionally downregulate its activity during leukemic progression (Mavrakis et al., 2011) .
Myc Deletion Specifically Targets LICs in an Animal
Model of T-ALL Given that leukemia-initiating capacity was found to be restricted to the Myc GFP+ population, we tested whether the depletion of Myc could specifically ablate LIC activity in T-ALL. Primary T-ALLs were generated from Myc F/F Mx1-Cre + or Myc +/+ Mx1-Cre + donors, and recipients were injected with pI:pC 2 weeks later, after leukemic cells were detected in the periphery. Our initial observation was that leukemic burden was decreased in recipients in which c-Myc expression was deleted ( Figure 4A) . Strikingly, the LIC-enriched DN3 subset was almost completely absent in the Myc-deficient leukemias ( Figure 4B ), suggesting that the LIC population absolutely depends on c-Myc function Mertz et al., 2011; Zuber et al., 2011) . One of these molecules, JQ1, was shown to effectively inhibit the expression and function of MYC, and it inhibited cell growth in multiple myeloma and acute myeloid leukemia (Filippakopoulos et al., 2010; Mertz et al., 2011) . To determine whether the inhibition of BRD4 could similarly lead to growth inhibition in T-ALL, we initially compared retroviral shRNA knockdown of Myc and Brd4 in Notch1 + mouse T-ALL cell lines. A significant loss of representation over time was observed in populations expressing shRNA targeting either gene ( Figure S5A ). The growth effect induced by the MYC hairpins was on target, given that complementation with non-RNA interference (RNAi)-targeted MYC cDNA restored their growth potential ( Figure S5B ). See also Figure S5 .
To start addressing the putative leukemia-targeting properties of BET inhibitors, we tested the growth of human T-ALL lines in the presence of varying concentrations of JQ-1 in vitro (Figure 5A) . A significant decrease in cell growth was observed after 4 days of JQ-1 treatment in a dose-dependent manner. BrdU incorporation assays and AnnexinV staining suggested that JQ-1 treatment resulted primarily in growth arrest rather than apoptosis ( Figures 5B-5C ). Given that previous work has shown that FBXW7 mutations conferred resistance to gamma-secretase inhibitors (GSIs) (Real et al., 2009; Thompson et al., 2007) , response to JQ-1 or GSI (Compound E) was compared in FBXW7 mutant or WT T-ALL lines ( Figure 5D ). As expected, GSI treatment inhibited the growth of HPB-ALL cells (WT FBXW7) but was significantly less effective in CEM or Jurkat T cells (both FBXW7 mutants). However, all T-ALL lines were unable to grow in the presence of JQ-1. The observed growth arrest was due, at least in part, to a loss of c-Myc, given that JQ-1 treatment resulted in a significant reduction in c-Myc protein expression in all T-ALL lines tested ( Figure 5E ) and overexpres- sion of c-Myc partially restored proliferation of the treated cells ( Figure 5F ). Altogether, these results show that BET bromodomain inhibitors are an appealing alternative to GSI treatment because they are able to target T-ALL cells irrespective of FBXW7 mutations.
In order to determine the in vivo efficacy of BET inhibitors with mouse T-ALL models, it was necessary to establish an in vitro system to maintain and expand c-Myc GFP+ LICs. Primary Notch1DE + c-Myc GFP+ splenocytes lose expression of c-Myc GFP and fail to expand in liquid culture ( Figure S5C ). However, when cocultured on OP9 stromal line in the presence of IL-7, these cells maintain their expression of c-Myc GFP ( Figure S5C ) and can be expanded indefinitely. Upon treatment with JQ-1, expression of c-Myc GFP rapidly returns to basal levels ( Figure 6A ) and the growth of the T-ALL cells is significantly inhibited ( Figure 6B ). To study the effect of BET bromodomain inhibitors on the progression of T-ALL in vivo, we utilized a derivative of JQ1, CPI203 (Devaiah et al., 2012) , which has shown superior bioavailability with oral or intraperitoneal (i.p.) administration. The EC 50 of CPI203 was nearly 3-fold lower than JQ-1 (91.2 versus 263 nM) when tested on a primary mouse T-ALL in vitro ( Figure 6B ), and this corresponded to a decrease in Myc mRNA ( Figure 6C ). To measure the effect of CPI203 in vivo, two independently derived primary mouse T-ALL samples, either Fbxw7 +/+ or Fbxw7 mut/+ , were transduced with a lentiviral luciferase reporter and each transplanted into two recipient animal groups, one treated with CPI203 (5 mg kg
À1
, BID) and the other with vehicle, and disease progression was monitored by in vivo luciferase imaging (IVIS Lumina) (Figure 6D) . A significant and rapid reduction in leukemia burden was observed in both the recipient groups treated with CPI203 ( Figures 6D-6E) , thus demonstrating the therapeutic potential of this compound for use in vivo.
Finally, we tested the response of primary human T-ALL patient samples (all with activating NOTCH1 mutations ± FBXW7 missense mutations) to both JQ1 and CPI203. Typically, a 2-to 3-fold reduction in cell growth occurred upon treatment with either compound across all genotypes ( Figure S6A) . Similarly to what was observed in the cell lines, this effect could be attributed mainly to cell-cycle arrest ( Figure S6B ), although a modest induction of apoptosis was also observed in two of the samples (Figure S6C) . Altogether, these data indicate significant potential for BET inhibitors for clinical use in the treatment of T-ALL.
BET Inhibitors Target the Notch and Myc Oncogenic Transcriptional Program
Brd4 functions as a chromatin reader by binding acetylated histones and recruiting effectors of transcriptional elongation, thereby promoting gene activation (Hargreaves et al., 2009 ). Thus, we hypothesized that Brd4 inhibition might have profound effects on T-ALL gene expression. High-throughput RNA sequencing (RNA-seq) was performed in CUTLL1 cells after treatment with inhibitor to assess immediate consequences on transcription genome wide. A total of 1,696 genes were downregulated, and 1,287 genes were upregulated upon JQ-1 treatment for 12 hr (400 nM) in comparison to vehicle-treated control (Max FPKM > 5, fold change > 1.3, q < 0.05) ( Figure 7A ). Interestingly, 28% of genes downregulated upon JQ-1 treatment were also overexpressed in the Myc GFP+ LIC population in our mouse T-ALL model ( Figure 3F ). High-throughput chromatin immunoprecipitation sequencing (ChIP-seq) for c-Myc and Brd4 was performed in CUTLL1 cells to assess their genome-wide occupancy. A total of 6,335 genes had significant c-Myc binding, and 6,874 genes showed Brd4 occupancy. Using available Notch1 and Rbpj ChIP-seq data , we compared the 7,526 genes also bound by both of these factors. A significant fraction of all occupied genes (3,282 of 9,453) showed binding for all three of these factors, suggesting an overlapping regulatory network ( Figure 7B ). As expected, a large portion of genes that were downregulated upon JQ-1 treatment also showed high promoter-read density for Brd4, c-Myc, or Notch1 ( Figure 7C ). Accordingly, a specific loss of Brd4 binding is observed at target gene promoters and enhancers ( Figure S7 ), and this loss is to a greater extent than Brd2, demonstrating some specificity of BET inhibition. In order to investigate the impact of c-Myc and Brd4 binding on direct targets of Notch and Rbpj, we categorized expressed genes (FPKM > 5) on the basis of the presence of all three factors, c-Myc, Notch1 only, or Notch1 alone. We found that genes with Brd4, c-Myc, and Notch1 binding have significantly higher expression than those with Notch binding alone. Genes with Brd4, c-Myc, and Notch1 binding or c-Myc and Notch1 binding also showed significantly higher RNA PolII density at their promoters, implying that the presence of c-Myc and Brd4, in addition to Notch1 at promoters, enhances transcriptional activity. Altogether, these data suggest that, especially in the context of FBXW7 mutations, higher thresholds of c-Myc work together with Notch1 activation to amplify a subset of genes critical for leukemic transformation.
DISCUSSION
The presented study sheds light on the selection of FBXW7 mutations during the evolution of leukemia genomes and the significant bias for missense (but fewer nonsense, insertion, or deletion) mutations in human T-ALL. The differential function of FBXW7 mutations could be explained by the existence of distinct thresholds of c-Myc expression between normal and malignant stem cells. This observation reveals a potential therapeutic window for the modulation of Fbxw7 and Myc activity in the treatment of human cancers. Indeed, we were able to show that Myc deletion suppresses established T-ALL by eliminating LICs and that pharmacologic targeting of c-Myc induction restricted the growth of human and mouse T-ALL, including those that carry FBXW7 mutations and are resistant to Notch inhibition. Another important finding illustrated here is that we are able to visualize LICs using in vivo genetic fluorescent labeling. Using the c-Myc GFP reporter strain, we were able to demonstrate that LICs can be purified on the basis of c-Myc protein abundance. T-ALL LICs have a characteristic surface phenotype, and their gene expression patterns correlate to gene signatures characteristic of earlier stages of differentiation, including HSCs and ESCs. Interestingly, a large proportion of these LIC-specific genes are bound by c-Myc and Notch1, both of which are key oncogenes in T-ALL. Brd4 is also present at most of these loci, a finding that can explain the therapeutic efficacy of BET inhibitors. Moreover, we observed that c-Myc expression directly correlated to LIC populations in vivo. Accordingly, human T-ALL LIC-enriched populations also express high levels of c-Myc protein, and FBXW7 mutations lead to significant c-Myc stabilization, suggesting that this mechanism is evolutionarily conserved. However, this is not a universal characteristic of tumor-initiating cell populations. Indeed, we have recently performed studies using animal models of BCR-ABL-driven chronic myelogenous leukemia, a prototypic LIC-driven disease. In this leukemia model, c-Myc expression does not define the cell population that has the ability to initiate and propagate disease (Reavie et al., 2013) , suggesting that different oncogenes and cellular settings could have distinct requirements for c-Myc expression and function.
Although c-Myc is critical in the development of a wide range of tissues, recent studies have suggested that c-Myc inhibition is surprisingly well tolerated, at least in preclinical animal studies (Soucek et al., 2008) . Initially, the inhibition of the Notch pathway with GSIs was a promising therapeutic approach, but it has presented considerable challenges (gastrointestinal toxicity and acquisition of resistance, for example) for its adaptation in the clinic. Here, we show that genetic inactivation of Myc in established T-ALL specifically targeted the LIC fraction, eventually leading to tumor regression and loss of LIC self-renewal. Similarly, treatment of human T-ALL lines and primary leukemic cells with BET inhibitors (JQ1 and CPI203) completely suppressed c-Myc response, leading to rapid growth arrest. Unlike GSI treatment, this effect is irrespective of FBXW7 status, suggesting such compounds could have broader applications across tumor genotypes. It remains to be seen whether BET inhibition will be as efficient for the treatment of either relapsed T-ALL or highly aggressive T-ALL subtypes, including early T cell progenitor T-ALL, which is also resistant to Notch pathway inhibition .
The combination of disease modeling to whole-genome and transcriptome studies lead to findings that could have major implications for the understanding of oncogenic (Notch and Myc) interactions and their role in gene expression regulation and cancer initiation. Our studies show that Notch1 is not sufficient to induce or maintain transplantable T-ALL in the absence of c-Myc. Interestingly, we demonstrate that the majority of LICspecific genes are bound by both transcription factors, but deletion of Myc can abrogate LIC activity. In agreement to this notion, it has been shown in vitro that MYC overexpression can induce resistance to Notch pathway inhibition . Thus, we hypothesize that Notch1 acts as a pioneering factor, influencing lineage commitment and the activity of epigenetic regulators (Ntziachristos et al., 2012) , altering the chromatin structure of its transcriptional targets to a more permissive state. When c-Myc becomes expressed and stabilized (because of the mutation or downregulation of FBXW7), it can bind to newly accessible E box motifs, thereby amplifying established gene-expression programs ( Figure 7C ). These studies support, in an in vivo tumor model, the recently postulated ''MYC transcriptional amplification'' hypothesis (Lin et al., 2012; Nie et al., 2012) . They also prove that this transcriptional amplification mode has in vivo consequences in cancer initiation and can be pharmacologically targeted. Finally, our studies show that such key transcriptional responses can be posttranslationally regulated and that oncogenic events invent ways to hijack them, as shown with in vivo modeling of the FBXW7 missense mutations.
EXPERIMENTAL PROCEDURES
Mice c-Myc GFP knockin and Myc conditional knockout mice were as described previously (de Alboran et al., 2001; Huang et al., 2008) . Fbxw7 knockin mutant mice were generated by the insertion of a loxP-flanked splice acceptor PGK-NEO cassette with three polyA sites in the intronic sequence between exons 10 and 11, and a CCG-to-GCA point mutation was introduced by PCR mutagenesis in the opposite strand at a coding sequence corresponding to R468. Eef1a1 human FBXW7 R465C mice were generated by introducing an R465C mutation into an N-terminally FLAG M2-tagged human FBXW7 alpha cDNA and subcloning this sequence into an Eef1a1 lox-STOP-lox targeting vector, as described previously (Buonamici et al., 2009) . Inducible Cre recombinase expression was achieved in Mx1-Cre mice by three consecutive i.p. injections of poly(I):poly(C) (15 mg kg
À1
, GE Healthcare). CPI203 (Constellation Pharmaceuticals) was dissolved in 5% DMSO and 10% hydroxypropyl-beta cyclodextrin and administered by i.p. injection twice daily at 5 mg kg À1 . All animal experiments were done in accordance with the guidelines of the NYU School of Medicine or the Columbia University Institutional Animal Care and Use Committee.
Bone Marrow Transduction and Transplantation BM was enriched for hematopoietic stem and progenitor cells by the magnetic selection of cells expressing c-kit (STEMCELL Technologies) cultured in the presence of 50 ng/ml SCF, 50 ng/ml Flt3 ligand, 10 ng/ml IL-3, and 10 ng/ml IL-6 and infected with concentrated retroviral supernatants after 24 and 48 hr. Transduction efficiency was determined by reporter fluorescence at 96 hr, and total or sorted populations were transferred via retroorbital injection into irradiated (1,100 rad) congenic recipients along with 2 3 10 5 unfractionated bone marrow mononuclear cells (BMMCs) for hemogenic support. Sublethally irradiated (450 rad) mice were used for secondary transplants. For Notch1 T-ALL induction, 5 3 10 4 Notch1DE GFP + BM cells were transferred per recipient, unless otherwise stated.
In Vitro Drug Treatments
Human and mouse T-ALL lines were grown in complete RPMI media (supplemented with 10% fetal bovine serum, penicillin and streptomycin, glutamine, and 55 mM b-mercaptoethanol). Primary mouse T-ALL were cocultured with OP9 stromal cells in Opti-MEM supplemented with 10% fetal bovine serum, 5 ng/ml IL-7, penicillin and streptomycin, glutamine, and 55 mM b-mercaptoethanol and passaged every 3-4 days onto a fresh feeder layer. JQ1 (Cayman Chemical) or Compound E (Alexis Biochemicals) prepared in DMSO was added to the cultures, and the media was replaced every 24 hr. BrdU (10 mM) was added for a 1 hr pulse, and incorporation into DNA was determined by using the BrdU Flow Kit (BD PharMingen).
Chromatin Immunoprecipitation
ChIP-seq was performed in CUTLL1 cells with rabbit polyclonal antibodies against c-Myc (N-262, Santa Cruz Biotechnology), Brd2 (Bethyl Laboratories, A302-583A), or Brd4 (Bethyl Laboratories, A301-985A) (5 mg per i.p. injection) as described previously (Ntziachristos et al., 2012) . Peak calling was performed with MACS1.4, allowing only one duplicate read. For Notch1, we considered only peaks with p < 10 3 10 À7 . For c-Myc and Brd4, we considered peaks with p < 10 3 10 À5 . Peak annotation was performed with a Cis-regulatory element annotation system. Genes were considered bound if a peak was present within 2 kb of the transcription start site.
Statistical Analysis
The means of each data set were analyzed using a Student's t test with a twotailed distribution and assuming equal sample variance.
ACCESSION NUMBERS
Raw expression data were deposited in the Gene Expression Omnibus under accession number GSE46797. 
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